Definitive Contract HHSN261201100110C

<p>This is a $1,494,102.45 cost-plus-fixed-fee contract awarded by the National Cancer Institute (a civilian agency) to Insight Genetics, Inc., a small business. The contract is for the development of a companion diagnostic for ALK mutations. It was awarded on September 28, 2012 and has a final completion date of February 5, 2015. This appears to be a stand-alone contract and not part of a larger contract vehicle.</p>

This is a $1,698,988.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), which is part of the U.S. Department of Health and Human Services (HHS), to Insight Genetics, Inc., a small business. The contract is for &quot;OTHER FUNCTIONS - R &amp; D BIOMEDICAL (BASIC RESEARCH)&quot; and has a total small business set-aside designation. The contract was awarded on September 20, 2012 and has an ultimate completion date of August 16, 2015. This contract award is not associated...

<p>The U.S. National Cancer Institute awarded a $200,000.00 firm fixed-price definitive contract to Insight Genetics, Inc., a small business, on September 30, 2010. The contract has a completion date of May 3, 2011 and was set aside for small businesses. The contract is for research and development services related to the National Cancer Institute's work, performed in Nashville, Tennessee.</p>

The U.S. National Cancer Institute (NCI) awarded a $1,499,990.00 cost-plus-award-fee contract to Insight Genetics, Inc. for research and development in the biomedical basic research field. The contract, which has a performance period through September 19, 2015, was awarded on September 20, 2013 and does not have a set-aside designation. While the original solicitation is not provided, this contract appears to be part of the NCI's larger research and development efforts in the medical and...

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Incogen Inc., a woman-owned small business. The contract, valued at $3,599,936, is for the development of &quot;GENE EXPRESSION SIGNAL PROCESSING TOOLS FOR EARLY DETECTION OF CANCER&quot; under Topic 197. It is a definitive, firm-fixed-price contract with a period of performance ending on December 14, 2009. The contract is set aside for small businesses.

This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute (NCI) to Inlighta Biosciences L.L.C., a woman-owned small business. The $298,230.00 firm fixed-price contract is for a Phase I Small Business Innovation Research (SBIR) project titled &quot;Non-Invasive Subtyping of Aggressive Tumor and Its Environment&quot; as part of the NCI Cancer Moonshot initiative. The original solicitation was issued under the NIH/CDC...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Personal Genome Diagnostics Inc., a for-profit company that provides molecular tissue testing services to federal agencies. The contract has a ceiling value of $222,994.00 and is a firm-fixed-price definitive contract for the development of a non-invasive approach to assess mutation load in tumors for treatment with...

<p>This is a $198,751 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Genomic Systems, LLC. The contract is for research and development in the TAS::75 0849::TAS area and has a period of performance ending on September 30, 2011. This SBIR Phase I contract was awarded on a Firm Fixed Price basis.</p>

<p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>